13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol

Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol

Malignant Hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder of skeletal muscle calcium homeostasis. Although most cesarean deliveries are performed under neuraxial blockade, general anesthesia is required in emergency scenarios (such as massive hemorrhage, failed regional block, or severe fetal distress). When exposed to triggering agents, susceptible individuals develop an uncontrollable hypermetabolic crisis with rapid rhabdomyolysis, severe hyperkalemia, acidosis, and cardiovascular collapse. Without prompt recognition and dantrolene administration, mortality exceeds 70-80% (reduced to <5% with modern protocols).

1. Genetic Pathophysiology & Triggering Agents

MH is inherited as an autosomal dominant trait with variable penetrance. In over 70% to 80% of families, the underlying defect involves a mutation in the Ryanodine Receptor 1 gene (RYR1) located on chromosome 19q13.1, or less commonly the voltage-gated L-type calcium channel alpha-1 subunit gene (CACNA1S).

+---------------------------------------------------------------------------------------------------+
|                         CELLULAR PATHOPHYSIOLOGY OF MALIGNANT HYPERTHERMIA                        |
|                                                                                                   |
|  • RESTING SKELETAL MUSCLE PHYSIOLOGY:                                                            |
|    - Ryanodine receptors (RYR1) control the efflux of calcium ($Ca^{2+}$) from the sarcoplasmic   |
|      reticulum (SR) into the sarcoplasm to initiate actomyosin cross-bridge muscle contraction.   |
|                                                                                                   |
|  • EXPOSURE TO TRIGGERING AGENTS:                                                                 |
|    - Mutated RYR1 channels exhibit abnormal, sustained channel opening upon exposure to triggers.  |
|    - Massive, uncontrolled efflux of $Ca^{2+}$ floods the myoplasm, overwhelming the SERCA         |
|      reuptake pumps.                                                                              |
|                                                                                                   |
|  • UNCONTROLLED HYPERMETABOLIC CASCADE:                                                           |
|    - Sustained myoplasmic $Ca^{2+}$ drives continuous actomyosin activation, causing sustained     |
|      muscle rigidity and extreme ATP consumption.                                                 |
|    - Cellular metabolism accelerates dramatically:                                                |
|      1. Aerobic glycolysis & oxidative phosphorylation skyrocket -> massive surge in $CO_2$ and   |
|         oxygen consumption.                                                                       |
|      2. Anaerobic metabolism takes over as oxygen is exhausted -> severe lactic acidosis.         |
|      3. Hydrolysis of ATP generates massive, uncontainable core heat (hyperthermia).              |
|                                                                                                   |
|  • CELL MEMBRANE COLLAPSE (Rhabdomyolysis):                                                       |
|    - Depletion of cellular ATP leads to sarcolemmal integrity failure, releasing myoglobin,       |
|      potassium ($K^+$), creatine kinase (CK), and lactate dehydrogenase into systemic circulation.|
+---------------------------------------------------------------------------------------------------+

Anesthetic Agents: Triggers vs. Safe Drugs

2. Clinical Presentation: Early Warning Signs vs. Late Manifestations

Recognizing the earliest signs of MH before hyperthermia develops is critical for maternal and fetal survival.

+---------------------------------------------------------------------------------------------------+
|                         PROGRESSION OF CLINICAL SIGNS IN MALIGNANT HYPERTHERMIA                   |
|                                                                                                   |
|  1. EARLIEST & MOST SENSITIVE CLINICAL SIGN:                                                      |
|     • **Unexplained, Rapid Rise in End-Tidal $CO_2$ ($ETCO_2$):**                                  |
|       - $ETCO_2$ doubles or triples (e.g., rising from 35 to >70-100 mmHg).                       |
|       - Persists despite aggressive increases in minute ventilation (doubling/tripling ventilator)|
|                                                                                                   |
|  2. EARLY SIGNS (Within Minutes):                                                                 |
|     • **Masseter Muscle Spasm (MMR / "Jaws of Steel"):**                                          |
|       - Inability to open mouth or intubate following succinylcholine administration.             |
|     • **Unexplained Sinus Tachycardia:** Earliest cardiovascular sign (sympathetic activation).   |
|     • **Generalized Muscle Rigidity:** Tense, wood-like abdominal wall and limb rigidity.         |
|     • **Mixed Severe Acidosis:** Combined respiratory and metabolic acidosis ($pH <7.15$,          |
|       $PaCO_2 >60	ext{ mmHg}$, base excess $<-8	ext{ mEq/L}$, Lactate $>8-10	ext{ mmol/L}$).   |
|                                                                                                   |
|  3. LATE / CONFIRMATORY SIGNS:                                                                    |
|     • **Fulminant Hyperthermia:** Core body temperature rises rapidly (1–2°C every 5 min), |
|       often reaching **>40°C to 43°C (104°F to 110°F)**.                                          |
|     • **Severe Hyperkalemia:** Peaked T-waves, widened QRS, ventricular fibrillation, asystole.    |
|     • **Massive Rhabdomyolysis:** Serum Creatine Kinase (CK) $>10,000-100,000+	ext{ IU/L}$,      |
|       myoglobinuria (dark red / tea-colored urine), and acute tubular necrosis / renal failure.    |
|     • **Disseminated Intravascular Coagulation (DIC):** Profuse microvascular bleeding, oozing    |
|       from cesarean hysterotomy and IV sites, profound thrombocytopenia, and consumption of       |
|       fibrinogen ($<100	ext{ mg/dL}$).                                                            |
+---------------------------------------------------------------------------------------------------+

Masseter Muscle Spasm (MMR) Protocol: If isolated masseter muscle rigidity occurs after succinylcholine, the anesthesiologist should immediately suspect MH. If surgery is emergent (e.g., crash cesarean), proceed with non-triggering agents (Propofol + Rocuronium), insert charcoal filters, monitor $ETCO_2$ continuously, and prepare Dantrolene.

3. Emergency Management & The Dantrolene Rescue Protocol

+---------------------------------------------------------------------------------------------------+
|                         STEP-BY-STEP MALIGNANT HYPERTHERMIA EMERGENCY PROTOCOL                     |
|                                                                                                   |
|  STEP 1: DISCONTINUE TRIGGERS & HYPERVENTILATE WITH 100% OXYGEN                                   |
|  • Immediately turn off all volatile anesthetic vaporizers and halt succinylcholine infusions.    |
|  • Call for help, the **MH Cart**, and notify the surgical/OB team to halt or conclude surgery.   |
|  • Hyperventilate with **100% $O_2$ at maximum fresh gas flow (≥10–12 L/min)**.         |
|  • Attach **Activated Charcoal Filters (Vapor-Clean)** to both inspiratory and expiratory limbs of |
|    the anesthesia circuit. (Do NOT delay resuscitation to change the anesthesia machine).         |
|                                                                                                   |
|  STEP 2: ADMINISTER DANTROLENE SODIUM IMMEDIATELY (DEFINITIVE ANTIDOTE)                           |
|  • **Dantrolene Loading Dose: 2.5 mg/kg IV push** as rapidly as possible.                         |
|  • Repeat bolus of **2.5 mg/kg IV every 5 to 10 minutes** until $ETCO_2$ normalizes, muscle       |
|    rigidity subsides, heart rate slows, and temperature stabilizes (cumulative dose may exceed     |
|    **10 mg/kg** in severe cases).                                                                 |
|  • Reconstitution Formulations:                                                                   |
|    - *Traditional Dantrolene (Dantrium / Revonto):* 20 mg/vial reconstituted in **60 mL sterile   |
|      water** without bacteriostatic agents (each vial contains 3 g mannitol). Requires multiple   |
|      personnel to reconstitute 8-10 vials (~200 mg for an 80 kg patient).                         |
|    - *Nanocrystalline Dantrolene (Ryanodex):* **250 mg/vial reconstituted in only 5 mL sterile    |
|      water** in <20 seconds. Administer 2.5 mg/kg IV push in seconds.                             |
|                                                                                                   |
|  STEP 3: ACTIVE CORE COOLING                                                                      |
|  • Administer **cold IV normal saline** (1,000 mL cold crystalloid over 10-15 minutes).           |
|  • Apply ice packs to high-flow vascular areas (groin, axillae, neck). Lavage open surgical       |
|    wound, bladder (via Foley), and stomach with cold sterile saline.                              |
|  • **CRITICAL RULE:** **STOP all active cooling when core temperature reaches 38.5°C (101.3°F)**  |
|    to prevent overshoot hypothermia and shivering.                                                |
|                                                                                                   |
|  STEP 4: TREAT HYPERKALEMIA & METABOLIC ACIDOSIS                                                  |
|  • For Hyperkalemia ($K^+ >5.5-6.0	ext{ mEq/L}$ or ECG changes):                                 |
|    - **Calcium Chloride 10% (10 mg/kg IV / 10 mL)** or Calcium Gluconate (30 mg/kg IV) to        |
|      stabilize cardiac myocyte membranes.                                                         |
|    - **Regular Insulin 10 units IV + Dextrose 50% (D50W 50 mL / 25 g)** to shift potassium into    |
|      cells.                                                                                       |
|  • For Severe Acidosis: **Sodium Bicarbonate 1–2 mEq/kg IV** titrated to arterial blood gas base  |
|    deficit ($pH >7.20$).                                                                          |
|  • **ABSOLUTE CONTRAINDICATION: Calcium Channel Blockers (Diltiazem, Verapamil)** are strictly     |
|    contraindicated in MH—concurrent use with dantrolene causes fatal hyperkalemia and myocardial   |
|    collapse!                                                                                      |
|                                                                                                   |
|  STEP 5: MAINTAIN RENAL DIURESIS & MONITOR COAGULOPATHY                                            |
|  • Maintain urine output **>1 to 2 mL/kg/hour** with IV fluids and Mannitol/Furosemide to protect  |
|    renal tubules against myoglobin precipitation and acute tubular necrosis.                      |
|  • Transfuse blood products (FFP, Cryoprecipitate, Platelets) for DIC.                            |
|                                                                                                   |
|  STEP 6: ICU POST-CRISIS CARE & MHAUS 24/7 HOTLINE                                                |
|  • Call the **MHAUS 24-Hour Hotline: 1-800-644-9737 (1-800-MH-HYPER)** for real-time guidance.    |
|  • Transfer to ICU for >=24 to 48 hours of continuous monitoring.                                 |
|  • Continue **maintenance Dantrolene 1 mg/kg IV every 4 to 6 hours** (or 0.25 mg/kg/hr continuous |
|    infusion) for at least 24 hours to prevent recrudescence (occurs in ~20% of cases).           |
+---------------------------------------------------------------------------------------------------+

4. Obstetric & Perinatal Considerations in MH

1. Fetal Physiological Impact: Maternal hypermetabolism, severe maternal hypercarbia, hypoxemia, and uterine vasoconstriction lead to rapid, severe fetal acidosis and fetal distress (prolonged fetal bradycardia or non-reassuring heart rate tracings).
2. Obstetric Management Timing: If MH occurs prior to delivery, maternal stabilization with 100% $O_2$, hyperventilation, and dantrolene must take priority. Emergent delivery is performed once maternal resuscitation is initiated.
3. Placental Transfer of Dantrolene: Dantrolene is highly lipophilic and readily crosses the placenta (fetal-to-maternal ratio ~0.8). Neonates may exhibit transient hypotonia, lethargy, and mild respiratory depression. A dedicated neonatal resuscitation team must be present at delivery.
4. Diagnostic Confirmation & Family Counseling: Following recovery, the patient and first-degree relatives should be referred for genetic testing for RYR1 and CACNA1S mutations, or the gold-standard in vitro Caffeine-Halothane Contracture Test (CHCT) performed on a fresh skeletal muscle biopsy.